No Data
No Data
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
Alice (688578): Volmetinib dosage is rapidly monitoring progress in the research pipeline
Alice announced its 2023 annual report and 2024 quarterly report. The company achieved operating income of 2,018 billion yuan in 2023, +155.1% year over year; net profit to mother was 644 million yuan, +393.5% year over year; deducted
Alice (688578.SH): Net profit in 2023 increased 393.54% year-on-year, and plans to pay 10 to 4 yuan
On April 25, Ge Longhui (688578.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2,018 billion yuan, an increase of 155.14%; net profit attributable to shareholders of listed companies was 644 million yuan, an increase of 393.54%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 606 million yuan, an increase of 663.70% year on year; basic income per share was 1.43 yuan/share. It is proposed to distribute a cash dividend of $4.00 (tax included) for every 10 shares.
Express News | Alice: Net profit from mother in the first quarter was 306 million yuan, an increase of 777.51% year-on-year
A-share changes | Alice rose more than 8% to record high clinical trial of injectable AST2169 liposomal drug approved
Glonghui, March 14 | Alice (688578.SH) is now up more than 8%, rising to a new high listing price of 50.27 yuan, with a total market value of 22.36 billion yuan. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study on the safety, tolerability, pharmacokinetics and initial curative effects of self-developed AST2169 liposomes in patients with advanced solid tumors with KRAS G12D mutations was approved for drug clinical trials.
Alice (688578.SH): AST2169 approved to conduct clinical trials for patients with advanced solid tumors with KRAS G12D mutations
Alice (688578.SH) announced that the company recently received from the China Drug Administration (“State Drug Administration”)...
No Data